NCT04452084View on ClinicalTrials.gov

Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions
Brain Metastases
Interventions
RADIATION

HA-WBRT

The accepted standard HA-WBRT doses in the control arm are 30Gy in 10 fractions.

RADIATION

HA-SIB-WBRT

The doses selected for experimental HA-SIB-WBRT arm are 30Gy in 10 fractions to the whole brain with 40 to 45Gy in 10 fraction SIB doses to tumours.

Trial Locations (1)

168583

National Cancer Center Singapore, Singapore

All Listed Sponsors
collaborator

Singhealth Duke-NUS Oncology Academic Clinical Programme (ONCO ACP)

UNKNOWN

collaborator

Singapore General Hospital

OTHER

lead

National Cancer Centre, Singapore

OTHER

NCT04452084 - Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT | Biotech Hunter | Biotech Hunter